Search

Objective To explore the effect of transurethral plasma prostate enucleation (TUKEP; Transurethral plasma enucleation of the prostate) on IPSS, QoL score, and in patients with prostatic hyperplasia. Methods 100 patients with Phyperplasia admitted to our hospital from January 1,2017 to September 1,2021 were selected as the subjects of this study・ According to the different treatment methods adopted by patients, 50 cases of observation group and control group, the control group underwent transurethral electric resection of the prostate (TURP; Transurethral electrical resection of the prostate), the observation group underwent transurethrfd plasma enucleation of the prostate, observe and compare the surgical conditions of the two groups (intraoperative blood loss, operation time, quality of prostate resection, bladder washing time, indwlling catheter time, etc.), residual urine volume before and after treatment (PVR; postvoid residual), international prostate symptom score (IPSS), patient quality of life (QoL; quality of life) score, maximum urinary flow rate (Q彌;Maximum urinary flow rate), postoperative complications. Results Hie operation time, bladder irrigation time, indwelling catheter time, and intraoperative blood loss of the observation group were (106・ 45 ± 18・ 29) min, (58・ 24 ± 17・ 23) mL, (3・ 53 ±0・ 92) d, and (19・ 45 ± 1.62) h respectively, and significantly shorter than the control group (132.76 ±32.11) min, (120,05 ±26.79) mL, (5.73 ±1.13) d, (27-74 ±4.12) h. Tlie excised tissue weight (55.76 ±16.43) g was higher than that of the control group (48・27 ±24・ 89) g, the difference was statistically significant (P <0・ 05); 3 months after the operation, the two groups of patients were improved to a certain extent, and the IPSS score, RUV value of the observation group were (5.95±l・08), (21.38 土2.12) mL was significantly lower than the control group (7・ 10 ± 0.94), (24.01 ± 2.31) mL, Q却 value (20・ 57 土 0・ 97) mL/s. It was significantly higher than the control group (17・ 88 ± 1.16) mL/s, and the difference was statistically significant (P <0.05). There was no significant difiference in the QoL score between the two groups after operation (P >0・ 05). Hie incidence of complications in the observation group was 5. 00% (3/50) was significandy lower than 16.00% (8/50) of the control group, and the difiference was statistically significant (P <0,05)・ Condusion Transurethral plasma enucleation of the prostate has a significant therapeutic effect on patients with benign prostatic hyperplasia. It can effectively improve IPSS, QoL scores and, with fewer postoperative complications and higher safety. [ABSTRACT FROM AUTHOR]

Objective To explore the inhibitory effects of Qizhi Tongqiao capsule (QTC) on rat prostatic hyperplasia induced by exogenous testosterone propionate and mechanisms. Methods A total of 27 male SD rats were included in this study and divided into 3 groups randomly and averagely as normal control group, benign prostatic hyperplasia (BPH) model group and QTC treatment group. BPH rat models were established through subcutaneous injection with testosterone propionate (Smg/kg/d). Powder suspension of QTC was given orally for 28 days (1. 52g/kg/d), then rats were all executed. Body weight and prostatic wet weight were recorded and prostate tissues were obtained. Pathological changes of the rat prostate were examined by HE staining. Protein expressions of Bax, Bcl-2, PCNA, HIF-10'. and VEGF were tested through Western blotting. Results Compared with the control group, the prostatic wet weight and prostatic index of rats in the model group both elevated significantly (P < 0. 01) which can be inhibited by orally-administered QTC (P < 0. 01, P < 0. 05). HE staining results indicated in the model group the prostatic epithelial became thicker (P < 0. 01) and lumen area decreased than in the control group, which can be improved by orally-administered QTC (P < 0. 01). Compared with the control group, protein expressions of Bcl-2, PCNA, HIF-1 C'. and VEGF significantly increased while protein expression of Bax and Bax/Bcl2 ratio significantly decreased in the prostatic tissues of rats in the model group (P < 0. 01). However, protein expressions of Bcl-2, PCNA, HIF-10'. and VEGF can be significantly inhibited and Bax/Bcl-2 ratio was markedly elevated with QTC treatment (P < 0. 01). Conclusion QTC treatment can significantly impede rat BPH which was induced by subcutaneous injection with testosterone propionate and ameliorate pathologic changes of the prostate, inhibit prostatic epithelial thickening. And the inhibitory effects on Bcl-2, PCNA, HIF-10', VEGF protein expressions and improving effect on Bax/Bcl-2 ratio of QTC may partly explain why it works. [ABSTRACT FROM AUTHOR]

Objective To understand the level of subjective well-being of patients with prostate hyperplasia and its influencing factors, so as to provide reference for the implementation of measures to improve the level of subjective well-being of patients. Methods A total of 412 patients with prostatic hyperplasia were investigated by general demographic data questionnaire, Memorial University of Newfoundland Scale of happiness, Pittsburgh Sleep Quality Index, Self-rating anxiety Scale and self-management ability Scale. Results The subjective well-being score of patients with BPH was (21.17±8.36). The subjective well-being score of patients with BPH was positively correlated with the total score of self-management ability (P < 0.01, r=0.380), and negatively correlated with the total score of anxiety and Pittsburgh sleep quality (P < 0.01, r=-0.536; P < 0.01, r=-0.553); Multiple linear regression analysis showed that family per capita monthly income, self-management ability, anxiety and sleep disturbance were the main influencing factors of SWB (P < 0.01), which could explain 38.9% of the total variation. Conclusion The subjective well-being of patients with BPH is at a moderate level. It is suggested that medical staff should pay attention to the improvement of patients’self-management ability, sleep quality and mental health education, so as to improve the level of subjective well-being of patients. [ABSTRACT FROM AUTHOR]